Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | G6PD | P11413 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL621605 | 1.00 | C5AR1 (0.40) | C5AR1DHODHNPSR1TLR9CYP24A1 | |
| SCHEMBL2596725 | 1.00 | C5AR1 (0.40) | C5AR1DHODHNPSR1TLR9CYP24A1 | |
| SCHEMBL3744998 | 0.84 | C5AR1 (0.38) | C5AR1DHODHNPSR1TLR9GAA | |
| SCHEMBL27358566 | 0.83 | C5AR1 (0.39) | C5AR1DHODHNPSR1TLR9CYP24A1 | |
| SCHEMBL15668772 | 0.82 | C5AR1 (0.37) | C5AR1DHODHNPSR1TLR9CYP24A1 | |
| SCHEMBL32668915 | 0.82 | CA2 (0.40) | C5AR1DHODHNPSR1TLR9CYP24A1 | |
| SCHEMBL15668771 | 0.82 | C5AR1 (0.37) | C5AR1DHODHNPSR1TLR9CYP24A1 | |
| SCHEMBL32668708 | 0.82 | CA2 (0.40) | C5AR1DHODHNPSR1TLR9CYP24A1 | |
| SCHEMBL17542475 | 0.81 | C5AR1 (0.38) | C5AR1DHODHNPSR1TLR9CYP24A1 | |
| SCHEMBL10932836 | 0.81 | GBA1 (0.46) | TLR9CYP24A1GAAALDH1A1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703802-B2 | Process for the preparation of aryl substituted olefinic amines | TARGACEPT, INC. (US) | 2014-04-22 | — | — | US | claimed |
| US-20250049809-A1 | INHIBITORS OF MUTANT IDH1 AND IDH2 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-02-13 | — | — | US | disclosed |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230271981-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-08-31 | — | — | US | disclosed |
| US-11685747-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2023-06-27 | — | — | US | disclosed |
| EP-3601297-B9 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2023-05-24 | — | — | EP | disclosed |
| CN-110691784-B | Compounds for inhibiting MCL-1 protein | 美国安进公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-20100249196-A1 | Novel Salt Forms Of (2S)-(4E)-N-Methyl-5-[3-(5-Isopropoxypyridin)yl]-4-Penten 2-Amine | ASTRAZENECA AB (SE) | 2010-09-30 | — | — | US | disclosed |
| US-20100121061-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100048643-A1 | Novel Polymorph Forms Of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine | TARGACEPT, INC. | 2010-02-25 | — | — | US | disclosed |
| EP-2133337-A1 | Salt forms of (2S)-(4E)-N-Methyl-5-[(5-Isopropoxy)pyridin-3-yl]-4-penten-2-amine | AstraZeneca AB (SE) | 2009-12-16 | — | — | EP | disclosed |
| EP-2133338-A1 | Salt forms of (2S)-(4E)-N-Methyl-5-[(5-Isopropoxy)pyridin-3-yl]-4-penten-2-amine | AstraZeneca AB (SE) | 2009-12-16 | — | — | EP | disclosed |
| EP-2021325-A2 | SALT FORMS OF (2S)-(4E)-N-METHYL-5-[3-(5-ISOPROPOXYPYRIDIN)YL]-4-PENTEN-2-AMINE | AstraZeneca AB (SE) | 2009-02-11 | — | — | EP | disclosed |
| EP-2021326-A1 | POLYMORPH FORMS OF (2S) - (4E) -N-METHYL-5- (3-ISOPROPOXYPYRIDIN) YL]-4-PENTEN-2-AMINE FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Targacept, Inc. (US) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007134034-A1 | POLYMORPH FORMS OF (2S) - (4E) -N-METHYL-5- (3-ISOPROPOXYPYRIDIN) YL] -4-PENTEN-2-AMINE FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007134038-A2 | SALT FORMS OF (2S)-(4E)-N-METHYL-5-[3-(5-ISOPROPOXYPYRIDIN)YL]-4-PENTEN-2-AMINE | ASTRAZENECA AB (SE) | 2007-11-22 | — | — | WO | disclosed |
| US-20070265314-A1 | NOVEL POLYMORPH FORMS OF (2S)-(4E)-N-METHYL-5-[3-(5-ISOPROPOXYPYRIDIN)YL]-4-PENTEN-2-AMINE | TARGACEPT, INC. | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265314-A1 | NOVEL POLYMORPH FORMS OF (2S)-(4E)-N-METHYL-5-[3-(5-ISOPROPOXYPYRIDIN)YL]-4-PENTEN-2-AMINE | HTR2B, CYP4B1, HTR3B | C5AR1 2028/4885DHODH 3607/4885NPSR1 928/4885 |
| US-20230271981-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL2L1, BCL9 | C5AR1 3754/4885DHODH 2817/4885NPSR1 4714/4885 |
| US-11685747-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL2L1, BCL9 | C5AR1 3754/4885DHODH 2817/4885NPSR1 4714/4885 |
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL2L1, BCL9 | C5AR1 3754/4885DHODH 2817/4885NPSR1 4714/4885 |
| US-20100249196-A1 | Novel Salt Forms Of (2S)-(4E)-N-Methyl-5-[3-(5-Isopropoxypyridin)yl]-4-Penten 2-Amine | SLC25A13, SLC25A11, SLC1A2 | C5AR1 3700/4885DHODH 127/4885NPSR1 814/4885 |
| US-20100048643-A1 | Novel Polymorph Forms Of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine | HTR2B, CYP4B1, HTR3B | C5AR1 2028/4885DHODH 3607/4885NPSR1 928/4885 |
| US-20250049809-A1 | INHIBITORS OF MUTANT IDH1 AND IDH2 | IDH1, IDH2, IDH3A | C5AR1 4870/4885DHODH 73/4885NPSR1 4775/4885 |
| US-20100121061-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | CHRM3, CHRM5, CHRM4 | C5AR1 259/4885DHODH 1423/4885NPSR1 31/4885 |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | C5AR1 3674/4885DHODH 3319/4885NPSR1 4685/4885 |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | C5AR1 3674/4885DHODH 3319/4885NPSR1 4685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.